These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30251577)

  • 1. Pragmatic clinical trials in the context of regulation of medicines.
    Gedeborg R; Cline C; Zethelius B; Salmonson T
    Ups J Med Sci; 2019 Jan; 124(1):37-41. PubMed ID: 30251577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of registries for post-marketing evaluation of medicines. A survey of Swedish health care quality registries from a regulatory perspective.
    Feltelius N; Gedeborg R; Holm L; Zethelius B
    Ups J Med Sci; 2017 Jun; 122(2):136-147. PubMed ID: 28276780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Series: Pragmatic trials and real world evidence: Paper 8. Data collection and management.
    Meinecke AK; Welsing P; Kafatos G; Burke D; Trelle S; Kubin M; Nachbaur G; Egger M; Zuidgeest M;
    J Clin Epidemiol; 2017 Nov; 91():13-22. PubMed ID: 28716504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013-2017.
    Brown JP; Wing K; Evans SJ; Bhaskaran K; Smeeth L; Douglas IJ
    BMJ Open; 2019 Oct; 9(10):e028133. PubMed ID: 31662354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Series: Pragmatic trials and real world evidence: Paper 7. Safety, quality and monitoring.
    Irving E; van den Bor R; Welsing P; Walsh V; Alfonso-Cristancho R; Harvey C; Garman N; Grobbee DE;
    J Clin Epidemiol; 2017 Nov; 91():6-12. PubMed ID: 28502812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase IV Studies: Some Insights, Clarifications, and Issues.
    Cesana BM; Biganzoli EM
    Curr Clin Pharmacol; 2018; 13(1):14-20. PubMed ID: 29651962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for the design of Phase 3 pharmaceutical trials that are more informative for patients, clinicians, and payers.
    Sonnad SS; Mullins CD; Whicher D; Goldsack JC; Mohr PE; Tunis SR
    Contemp Clin Trials; 2013 Nov; 36(2):356-61. PubMed ID: 23999501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Series: Pragmatic trials and real world evidence: Paper 6. Outcome measures in the real world.
    Welsing PM; Oude Rengerink K; Collier S; Eckert L; van Smeden M; Ciaglia A; Nachbaur G; Trelle S; Taylor AJ; Egger M; Goetz I;
    J Clin Epidemiol; 2017 Oct; 90():99-107. PubMed ID: 28502810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments.
    McGettigan P; Alonso Olmo C; Plueschke K; Castillon M; Nogueras Zondag D; Bahri P; Kurz X; Mol PGM
    Drug Saf; 2019 Nov; 42(11):1343-1351. PubMed ID: 31302896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmarketing evaluations help determine contraceptive safety, efficacy.
    Netw Res Triangle Park N C; 1988; 9(2):1-2, 7. PubMed ID: 12280950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
    Maier WC; Christensen RA; Anderson P
    Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory.
    Weinfurt KP; Hernandez AF; Coronado GD; DeBar LL; Dember LM; Green BB; Heagerty PJ; Huang SS; James KT; Jarvik JG; Larson EB; Mor V; Platt R; Rosenthal GE; Septimus EJ; Simon GE; Staman KL; Sugarman J; Vazquez M; Zatzick D; Curtis LH
    BMC Med Res Methodol; 2017 Sep; 17(1):144. PubMed ID: 28923013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing pragmatic trials-what can we learn from lessons learned?
    Groenwold RHH; Dekkers OM
    J Clin Epidemiol; 2017 Oct; 90():3-5. PubMed ID: 28629700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of pragmatic trials found a high degree of diversity in design and scope, deficiencies in reporting and trial registry data, and poor indexing.
    Nicholls SG; Carroll K; Hey SP; Zwarenstein M; Zhang JZ; Nix HP; Brehaut JC; McKenzie JE; McDonald S; Weijer C; Fergusson DA; Taljaard M
    J Clin Epidemiol; 2021 Sep; 137():45-57. PubMed ID: 33789151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights.
    Marchenko O; Russek-Cohen E; Levenson M; Zink RC; Krukas-Hampel MR; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):170-186. PubMed ID: 29714518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences.
    Oude Rengerink K; Kalkman S; Collier S; Ciaglia A; Worsley SD; Lightbourne A; Eckert L; Groenwold RHH; Grobbee DE; Irving EA;
    J Clin Epidemiol; 2017 Sep; 89():173-180. PubMed ID: 28502808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.